These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 3533125)

  • 1. The pharmacokinetics of intravenous and oral levodopa in patients with Parkinson's disease who exhibit on-off fluctuations.
    Hardie RJ; Malcolm SL; Lees AJ; Stern GM; Allen JG
    Br J Clin Pharmacol; 1986 Oct; 22(4):429-36. PubMed ID: 3533125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The "on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport.
    Nutt JG; Woodward WR; Hammerstad JP; Carter JH; Anderson JL
    N Engl J Med; 1984 Feb; 310(8):483-8. PubMed ID: 6694694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Importance of within subject variation in levodopa pharmacokinetics: a 4 year cohort study in Parkinson's disease.
    Chan PL; Nutt JG; Holford NH
    J Pharmacokinet Pharmacodyn; 2005 Aug; 32(3-4):307-31. PubMed ID: 16320098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 3-O-methyldopa and motor fluctuations in Parkinson's disease.
    Fabbrini G; Juncos JL; Mouradian MM; Serrati C; Chase TN
    Neurology; 1987 May; 37(5):856-9. PubMed ID: 3574690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complicated response fluctuations in Parkinson's disease: response to intravenous infusion of levodopa.
    Quinn N; Marsden CD; Parkes JD
    Lancet; 1982 Aug; 2(8295):412-5. PubMed ID: 6124807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and effects of levodopa in advanced Parkinson's disease.
    Bredberg E; Tedroff J; Aquilonius SM; Paalzow L
    Eur J Clin Pharmacol; 1990; 39(4):385-9. PubMed ID: 2076722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical pharmacokinetics of levodopa in parkinson's disease.
    Bianchine JR; Shaw GM
    Clin Pharmacokinet; 1976; 1(5):313-38. PubMed ID: 797502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease.
    Fabbrini G; Juncos J; Mouradian MM; Serrati C; Chase TN
    Ann Neurol; 1987 Apr; 21(4):370-6. PubMed ID: 3579222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
    Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
    Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repeated levodopa infusions in fluctuating Parkinson's disease: clinical and pharmacokinetic data.
    Marion MH; Stocchi F; Quinn NP; Jenner P; Marsden CD
    Clin Neuropharmacol; 1986; 9(2):165-81. PubMed ID: 3708602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Motor fluctuations during continuous levodopa infusions in patients with Parkinson's disease.
    Nutt JG; Carter JH; Lea ES; Woodward WR
    Mov Disord; 1997 May; 12(3):285-92. PubMed ID: 9159720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concentration-effect relationship of levodopa in patients with Parkinson's disease.
    Harder S; Baas H; Rietbrock S
    Clin Pharmacokinet; 1995 Oct; 29(4):243-56. PubMed ID: 8549026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Motor fluctuations in Parkinson's disease: pathogenetic and therapeutic studies.
    Mouradian MM; Juncos JL; Fabbrini G; Chase TN
    Ann Neurol; 1987 Oct; 22(4):475-9. PubMed ID: 3435068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symptoms and pharmacokinetics of levodopa in patients with Parkinson's disease.
    Yamamoto M; Yokochi M; Kuno S; Hattori Y; Tsukamoto Y; Narabayashi H; Tohgi H; Mizuno Y; Kowa H; Yanagisawa N; Kanazawa I
    J Neural Transm (Vienna); 1997; 104(2-3):229-36. PubMed ID: 9203084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of the effects of controlled-release levodopa (Madopar CR) with conventional levodopa in late Parkinson's disease.
    MacMahon DG; Sachdev D; Boddie HG; Ellis CJ; Kendal BR; Blackburn NA
    J Neurol Neurosurg Psychiatry; 1990 Mar; 53(3):220-3. PubMed ID: 2182781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic levodopa therapy enhances dopa absorption: contribution to wearing-off.
    Murata M; Mizusawa H; Yamanouchi H; Kanazawa I
    J Neural Transm (Vienna); 1996; 103(10):1177-85. PubMed ID: 9013404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Jejunal Infusion of levodopa-carbidopa intestinal gel versus oral administration of levodopa-carbidopa tablets in japanese subjects with advanced Parkinson's disease: pharmacokinetics and pilot efficacy and safety.
    Othman AA; Chatamra K; Mohamed ME; Dutta S; Benesh J; Yanagawa M; Nagai M
    Clin Pharmacokinet; 2015 Sep; 54(9):975-84. PubMed ID: 25875940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Intravenous infusion of L-dopa: current prospective therapies].
    Peppe A; De Angelis D; Tolli VS; Rizzo PA; Scoppetta C
    Riv Neurol; 1991; 61(5):197-200. PubMed ID: 1808680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peripheral pharmacokinetics of levodopa in untreated, stable, and fluctuating parkinsonian patients.
    Gancher ST; Nutt JG; Woodward WR
    Neurology; 1987 Jun; 37(6):940-4. PubMed ID: 3587644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients.
    Shoulson I; Glaubiger GA; Chase TN
    Neurology; 1975 Dec; 25(12):1144-8. PubMed ID: 812004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.